AbbVie Inc. Files 8-K on Financial Operations
Ticker: ABBV · Form: 8-K · Filed: 2024-04-03T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, debt-management, operations-report
Related Tickers: ABBV
TL;DR
AbbVie dropped an 8-K on 4/3 detailing its financial ops and notes due thru 2031.
AI Summary
On April 3, 2024, AbbVie Inc. filed an 8-K report detailing its financial condition and results of operations. The filing includes information on various senior notes due in 2024, 2027, 2028, 2029, and 2031, indicating ongoing financial management and debt obligations.
Why It Matters
This filing provides insight into AbbVie's current financial standing and its management of various debt instruments, which can impact investor confidence and future strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting financial information and does not indicate any unusual or negative events.
Key Numbers
- 2024 — Senior Notes Due (AbbVie has senior notes maturing in 2024, indicating short-term debt obligations.)
- 2027 — Senior Notes Due (AbbVie has senior notes maturing in 2027, indicating medium-term debt obligations.)
- 2028 — Senior Notes Due (AbbVie has senior notes maturing in 2028, indicating medium-term debt obligations.)
- 2029 — Senior Notes Due (AbbVie has senior notes maturing in 2029, indicating medium-term debt obligations.)
- 2031 — Senior Notes Due (AbbVie has senior notes maturing in 2031, indicating long-term debt obligations.)
Key Players & Entities
- AbbVie Inc. (company) — Filer of the 8-K report
- 1 NORTH WAUKEGAN ROAD (address) — Business and mailing address of AbbVie Inc.
- NORTH CHICAGO (city) — City of AbbVie Inc.'s headquarters
- IL (state) — State of AbbVie Inc.'s headquarters
- 60064 (zip_code) — Zip code of AbbVie Inc.'s headquarters
- 20240403 (date) — Filing date of the 8-K report
FAQ
What is the purpose of this 8-K filing by AbbVie Inc.?
The 8-K filing on April 3, 2024, is to report on AbbVie Inc.'s results of operations and financial condition, as well as to file financial statements and exhibits.
What specific financial instruments are mentioned in the filing related to debt?
The filing mentions several series of senior notes with various maturity dates, including those due in 2024, 2027, 2028, 2029, and 2031.
On what date was this 8-K report filed?
The 8-K report was filed on April 3, 2024.
What is AbbVie Inc.'s primary business classification according to the filing?
AbbVie Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where is AbbVie Inc. headquartered?
AbbVie Inc. is headquartered at 1 North Waukegan Road, North Chicago, IL 60064.
From the Filing
0001551152-24-000013.txt : 20240403 0001551152-24-000013.hdr.sgml : 20240403 20240403160609 ACCESSION NUMBER: 0001551152-24-000013 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240403 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240403 DATE AS OF CHANGE: 20240403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24818707 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 8-K 1 abbv-20240403.htm 8-K abbv-20240403 0001551152 false 0001551152 2024-04-03 2024-04-03 0001551152 us-gaap:CommonStockMember exch:XCHI 2024-04-03 2024-04-03 0001551152 us-gaap:CommonStockMember exch:XNYS 2024-04-03 2024-04-03 0001551152 exch:XNYS abbv:Sec1.375SeniorNotesDue2024Member 2024-04-03 2024-04-03 0001551152 abbv:Sec1250SeniorNotesDue2024Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec0.750SeniorNotesDue2027Member exch:XNYS 2024-04-03 2024-04-03 0001551152 abbv:Sec2.125SeniorNotesdue2028Member exch:XNYS 2024-04-03 2024-04-03 0001551152 exch:XNYS abbv:Sec2625SeniorNotesDue2028Member 2024-04-03 2024-04-03 0001551152 exch:XNYS abbv:Sec2125SeniorNotesDue2029Member 2024-04-03 2024-04-03 0001551152 exch:XNYS abbv:Sec1.250SeniorNotesdue2031Member 2024-04-03 2024-04-03 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  _____________________________________________________ FORM  8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): April 3, 2024   ABBVIE INC. (Exact name of registrant as specified in its charter) Delaware   001-35565   32-0375147 (State or other Jurisdiction   (Commission File Number)   (IRS Employer of Incorporation)       Identification No.)  _____________________________________________________ 1 North Waukegan Road North Chicago ,  Illinois 60064-6400 (Address of principal executive offices)(Zip Code)   Registrant’s telephone number, including area code:  ( 847 ) 932-7900   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐                       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐                       Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐                       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐                       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.01 Par Value   ABBV   New York Stock Exchange